Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals has announced the release of its full year results for the period ending December 31, 2024, scheduled for February 20, 2025. An investor webcast and conference call will take place the following day to discuss these results. This announcement is an important opportunity for stakeholders to gain insights into Telix’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company that focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, along with associated medical technologies. Headquartered in Melbourne, Australia, with operations in the United States, Canada, Europe, and Japan, Telix aims to address significant unmet medical needs in oncology and rare diseases through its clinical and commercial stage products.
YTD Price Performance: 27.84%
Average Trading Volume: 3,992
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.1B
For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.
